| 摘要 |
In the present invention, it has been discerned that Rhus verniciflua bark has an anti-inflammatory effect using a mouse in which inflammation is induced through 2,4-dinitroflurorobenzene (DNFB) and activated macrophages. As a result, the Rhus verniciflua bark decreases an increase in vascular permeability which is the properties of dermatitis having the clear histologic modification of the corium and epidermis and also decreases the expansion of the ear tissue and the hyperkeratinization of the ear tissue. It has been confirmed that the activity of mast cells is decreased in a goup in which Rhus verniciflua bark extracts are implanted through toluidine blue dyeing. The Rhus verniciflua bark extracts significantly decrease the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX-2) in activated macrophages during a translation step. In addition, the production of tumor necrosis factor-a (TNF-a) and interleukin 6 (IL-6) is significantly decreased when the Rhus verniciflua bark extracts are treated in the activated macrophages. This is a result which indicates that the control of iNOS, COX-2, and proinflammatory cytokines can be represented through NFkB signaling pathways. In conclusion, the Rhus verniciflua bark extracts can be variously utilized as a pharmaceutical composition and a health functional food for treating dermatitis (seborrheid, atopy, and contact dermatitis). |
